All News
JUNIPERA Study - Secukinumab in Juvenile PsA & ERA
JUNIPERA study evaluated secukinumab (SEC) in children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) and was found to be safe and effective in patients with active ERA and JPsA who previous failed to respond to conventional therapy.
Read Article
Black Adults Have a Higher Gout Risk
In a cross-sectional study of US adults, gout was more prevalent in black adults compared to white adults; possibly explained by sex-specific dietary differences and social determinants of health and clinical factors.
Read Article
Biosimilar switching is due to costs, formulary, relocation. Study of 23 studies, 3657 pts found only observational data, no RCTs. Ref product to biosimilar usually RCTs; Biosimilar switches usually real world evidence w/ good efficacy & no new risks. https://t.co/odAYHdbVd1 https://t.co/BabkVYsMBL
Links:
Dr. John Cush RheumNow ( View Tweet)
Are you a fan of the RheumNow podcast? Please rate, like and review us wherever you get your podcast. We'd appreciate it!
Dr. John Cush RheumNow ( View Tweet)
Recurrence of axSpA in 1st-degree relatives (FDR) probands w/ 35-yrs F/U. From 363 AS probands & 806 FDR, 27.1% of B27(+) FDR developed axSpA; 18.2% from AS probands; 4% from nr-axSpA probands. Recurrence higher with B27+ probands https://t.co/1xczXdtrH3 https://t.co/mXZ72nVAqp
Links:
Dr. John Cush RheumNow ( View Tweet)
UK Women’s Cohort -diet & Hip Fx risk study shows that amongst 26,318 women, 822 hip Fxs - Hip Fx risk was higher in Vegetarians (HR 1.33; 1.03, 1.71)) but not meat-eaters (HR 1.00; 0.85, 1.18) or pescatarians (0.97; 0.75, 1.26); unaffected by BMI https://t.co/tipy0IBp4D https://t.co/sG0lJAUgDj
Links:
Dr. John Cush RheumNow ( View Tweet)
Cochrane review of Stem cell transplantation in systemic sclerosis (3RCTs w/ 125 pts). Non‐myeloablative & myeloablative selective HSCT had moderate evidence for improved survival, skin thickness & function. But these had high Serious AE rates. https://t.co/d3CPsKiR88 https://t.co/QgCYBikhyl
Links:
Dr. John Cush RheumNow ( View Tweet)
Urine-soluble CD163 as a biomarker in #SLE: usCD163 significantly higher w/ active lupus nephritis & correlates w/ UPCR, disease activity, anti-dsDNA Ab levels and a higher chronic kidney disease stage. https://t.co/Mxe53pCnEF https://t.co/BOspodqpSE
Links:
Dr. John Cush RheumNow ( View Tweet)
Axial PsA frequency? Study of Derm identified PSO adults w/ chronic LBP, onset <45 yrs, not Rx w/ DMARDs--> 100 pts referred to Rheumatology; 14 pts dx w/ axPsA, 5 w/ peripheral PsA, & 3 w/ both axial & peripheral PsA https://t.co/oVxDcY17ZQ https://t.co/oIOfptskf3
Links:
Dr. John Cush RheumNow ( View Tweet)
Let’s look at the timeline of major discoveries in AxSpA genetics, starting with HLA-B27 in 1972 https://t.co/f3AvYJodQj
ASAS Official_ASAS ( View Tweet)
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study https://t.co/1fiNgBQUbr looks like lower ab response and drops over 6 mths - boosters important in our patients
Links:
Peter Nash drpnash ( View Tweet)
Global Mortality Rates for PsA, SpA and Colitis
Global age-standardized mortality rate (ASMR) for 1000000 was for 0.13 for AS, 0.04 for PsA, 0.86 for CD and 0.76 for UC.
https://t.co/0cZ9kZsiEM https://t.co/hDHojKBeRQ
Links:
Dr. John Cush RheumNow ( View Tweet)
NEJM - Lupus Pernio in Sarcoidosis - 71 yoM w/ red nodules on his nose, ears, fingers, and toes. The lungs were clear on auscultation. Angiotensin-converting enzyme level of 102. https://t.co/Vy9XQlRVKl https://t.co/wlyx3D9FzC
Links:
Dr. John Cush RheumNow ( View Tweet)
Utility of Repeat ENA Antibody Testing
Repeat serologic testing is not uncommon, but is it warranted? A retrospective study shows that repeated testing for autoantibodies to extractable nuclear antigens rarely changes the result or adds a new diagnosis.
https://t.co/ncXqSMz0Qo https://t.co/FxHKjJsga3
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 99 Henoch-Schönlein purpura (HSP) pts complicated by GI bleeding (61 mild; 38 severe). Severe GIB assoc w/ sufmmer Onset, facial rash, HI D-dimer (>0.89 mg/L) & neutrophil-to-lymphocyte ratio (NLR >10.56). https://t.co/sI5LoONWGf https://t.co/ySdswRfkMg
Links:
Dr. John Cush RheumNow ( View Tweet)
Should you do sural nerve biopsy (SNB) to Dx vasculitis? Study of 91 pts undergoing SNB suggests the SNB must be off sufficient length to improve Dx yield. 40/91 (44%) showed vasculitis. +SNB assoc w/ longer SNB sample, other organ Sxs & +ANCA https://t.co/6S00ySj0fL https://t.co/WbY400YsWX
Links:
Dr. John Cush RheumNow ( View Tweet)
More Bad Safety News for Xeljanz
Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in RA are higher than with TNF inhibitors.
https://t.co/iCrEofMjBR https://t.co/wAr1AuNGUw
Links:
Dr. John Cush RheumNow ( View Tweet)
Prospective study of 189 new non-infectious anterior uveitis pts, found a high prevalence SpA (56%), 93% w/ axial SpA, few (7) w/ peripheral SpA. 74/106 were newly Dx SpA. SpA predictors: psoriasis (OR 12.5), B27+ (OR 6.3),^CRP (OR 4.8) & male (OR 2.1) https://t.co/5UvH1oTFTb https://t.co/Zi6hH8q5VY
Links:
Dr. John Cush RheumNow ( View Tweet)
Lilly has announced that Taltz (ixekizumab) is now available as a Citrate-Free Formulation to reduce injection site pain for patients with psoriasis, psoriatic arthritis, spondyloarthritis & nonradiographic axial spondyloarthritis. https://t.co/mTBl9siLED https://t.co/TCFqdK58dA
Links:
Dr. John Cush RheumNow ( View Tweet)
We've got a lot to discuss this week: psoriasis; fatigue; sleep; sural nerve biopsies; uveitis and SpA; diet and RA; tofacitinib and the ORAL surveillance study; what not to take with mycophenolate - and more.
https://t.co/ctEQBEQpMn https://t.co/rLB6z2bhWc
Links:
Dr. John Cush RheumNow ( View Tweet)